Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 3
2005 1
2006 1
2007 3
2008 2
2009 3
2010 1
2011 3
2012 2
2013 4
2014 9
2015 7
2016 3
2017 3
2018 1
2019 4
2020 2
2021 2
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes.
White KL, Osman N, Cuadra-Foy E, Brenner BG, Shivakumar D, Campigotto F, Tsiang M, Morganelli PA, Novikov N, Lazerwith SE, Jin H, Niedziela-Majka A. White KL, et al. Antimicrob Agents Chemother. 2023 May 1;65(5):e02406-20. doi: 10.1128/AAC.02406-20. Epub 2021 Mar 1. Antimicrob Agents Chemother. 2023. PMID: 33649107 Free PMC article.
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.
Sax PE, Andreatta K, Molina JM, Daar ES, Hagins D, Acosta R, D'Antoni ML, Chang S, Martin R, Liu H, Blair C, McNicholl I, Gallant J, Collins SE, Martin H, White KL. Sax PE, et al. Among authors: white kl. AIDS. 2022 Sep 1;36(11):1511-1520. doi: 10.1097/QAD.0000000000003244. Epub 2022 Apr 23. AIDS. 2022. PMID: 35466963 Free PMC article.
Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
D'Antoni ML, Andreatta K, Acosta R, Martin H, Chang S, Martin R, White KL. D'Antoni ML, et al. Among authors: white kl. J Acquir Immune Defic Syndr. 2022 Apr 1;89(4):433-440. doi: 10.1097/QAI.0000000000002888. J Acquir Immune Defic Syndr. 2022. PMID: 34897227 Free PMC article. Clinical Trial.
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Andreatta K, Willkom M, Martin R, Chang S, Wei L, Liu H, Liu YP, Graham H, Quirk E, Martin H, White KL. Andreatta K, et al. Among authors: white kl. J Antimicrob Chemother. 2019 Dec 1;74(12):3555-3564. doi: 10.1093/jac/dkz347. J Antimicrob Chemother. 2019. PMID: 31430369 Free PMC article. Clinical Trial.
HIV-1 Proviral Sequence and Treatment Outcome of Virologically Suppressed Patients Switching to Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate.
Andreatta K, Chang S, Martin R, Acosta R, Daeumer M, Thielen A, Miller MD, White KL. Andreatta K, et al. Among authors: white kl. J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):e45-e51. doi: 10.1097/QAI.0000000000001757. J Acquir Immune Defic Syndr. 2018. PMID: 29781878 No abstract available.
52 results